HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
Provided By GlobeNewswire
Last update: Nov 14, 2024
Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule
SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data
Read more at globenewswire.comNASDAQ:HOOK (6/20/2025, 8:00:02 PM)
1.29
-0.01 (-1.15%)
Find more stocks in the Stock Screener
